January 2023 Working Group Meeting and FHIR Connectathon Guidelines
The HL7 meeting policies are predicated on our wish to provide a safe environment for all of our attendees and staff.
After reviewing the most current evidence provided by public health and safety experts, the HL7 International Board of Directors has determined that the January WGM and FHIR Connectathon can be the most productive, interactive and safest events possible by enacting the following policy:
- Proof of vaccination is not required
- Masks are strongly encouraged but not required
A negative COVID test is required for entry
All attendees are strongly encouraged to secure a negative COVID test within 72 hours prior to arriving to the WGM registration area.
- Acceptable test results may be from either a PCR or antigen tests from a lab or at-home tests
- Negative test results can be documented and displayed on paper or a photo (via cell phone)
- HL7 will provide an onsite COVID triaging services that expedites those with recent negative COVID test results (shorter line)
- HL7 will provide testing for those who did not secure a negative COVID test within 72 hours prior to arriving to the WGM venue (longer line)
- All attendees are strongly encouraged to secure a negative COVID test within 72 hours prior to arriving to the WGM registration area.
- Should any attendee test positive at the HL7-provided onsite COVID testing service, they will not be allowed to enter any of the HL7 events, and a pro-rated refund of the registration fees already paid will be provided
- If a potential COVID exposure occurs during the event (confirmed by onsite positive test results), all attendees will be alerted, allowing attendees to modify their behavior as they feel comfortable
By registering for this event, you acknowledge that you read and agree with the related COVID Policy. HL7 International is not responsible for any participants' travel related expenses such as airline or hotel cancellation fees should they cancel or if HL7 International is required to cancel. By attending an HL7 International event, you assume responsibility for the risk of injury or sickness and the related results of such an occurrence. You assume and accept these risks and release and waive HL7 International, its officers, employees, agents and contractors for any and all claims, suits and causes of action arising out of or related to any injury, sickness, infection and other related results.
HL7 International COVID Protection Policy
Approved by the HL7 Executive Committee on December 13, 2021
After review of the most current evidence provided by public health and safety experts, the HL7 International Board of Directors has determined that HL7 events can be the most robust, productive, interactive and safest conferences possible by requiring full COVID-19 vaccination (as defined by your country/domicile) for entry.
- HL7 will utilize an onsite company to confirm that the vaccination status and negative COVID testing results of each attendee and staff member complies with the applicable right of entry protocols.
- The onsite health professionals will conduct testing for those that did not obtain it prior to arrival at the cost of the attendee. The testing administered will be a Rapid Antigen test. The testing administered will cost $23 USD per test.
Right of Entry
HL7 will define specific Right of Entry Protocols that reflect these principles and that comply with prevailing public health guidelines and local public health regulations in the event location. As new developments arise over the coming months, HL7 will continue to refine adopt the most recent requirements for the Right of Entry Protocol as required.
At this time for the purposes of right of entry to HL7 events, a person is considered fully vaccinated:
- 2 weeks after their second dose in a 2-dose series, such as the Pfizer and Moderna vaccines, or
- 2 weeks after a single-dose vaccine, such as Johnson & Johnson's Janssen vaccine
This guidance applies to COVID-19 vaccines authorized for use and for emergency use by the U.S. Food and Drug Administration (i.e., Pfizer-BioNTech, Moderna, and Johnson and Johnson (J&J/Janssen COVID-19 vaccines), and COVID-19 vaccines authorized for emergency use by the World Health Organization (i.e., AstraZeneca/Oxford, Covishield, Sinopharm, and Sinovac), for which a second dose has been administered two weeks prior to the event start date.
The full list of vaccines with final WHO EUL/PQ evaluation status is available here. HL7 may expand the list of vaccines, provide more specific guidance regarding mixed vaccination dosing, and/or provide additional guidance regarding boosters as prevailing public health guidance evolves.
Watch this space for updates and additional details regarding specific events.